Q2 FY2026 EarningsQ2 FY26 missed consensus across all key financial metrics, with revenue reported at -$0.26M vs. the $3.45M expected, largely due to a reversal in collaboration revenue. GAAP EPS of -$0.73 was significantly wider than the -$0.55 consensus, driven by higher-than-expected operating losses reaching $28.8M. Despite the financial miss, the lead program MGX-001 remains on track for an IND submission in Q4 2026, with a cash runway extending through Q4 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Metagenomi Therapeutics(MGX) the Revenue is -257 K (-103%), Miss estimate;the EBIT is -28.77 M (-37.1%), Miss estimate;the EPS is -0.73 (-35.19%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
-0.00B103.02%
0.00B59.47%
-0.00B43.55%
EBITMiss expectations
-0.03B37.10%
-0.02B2.78%
-0.01B34.32%
EPSMiss expectations
-0.7335.19%
-0.5532.40%
-0.177032.79%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf